Nestle SA

Nestlé SA is a nutrition, health, and wellness company, which engages in the business of manufacturing, supplying, and producing prepared dishes and cooking aids, milk-based products, pharmaceuticals and ophthalmic goods, baby foods, and cereals. It operates through the following segments: Zone North America; Zone Europe; Zone Asia, Oceania, and Africa; Zone Latin America; Zone Greater China; Nestlé Health Science; and Nespresso. The company was founded by Henri Nestlé in 1866 and is headquartered in Vevey, Switzerland.

Aimmune Therapeutics

Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.

Nestle is paying $2.6 billion for a company that treats peanut allergies

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.
Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.

Here’s why Nestlé is buying a peanut-allergy company for $2.6B

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62871_5167b93204a2486d_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Aimmune Therapeutics, Inc. to Nestlé S.A.

Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.

Nestle To Buy Peanut Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

Why Aimmune Therapeutics Stock Is Soaring Today

The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.

Nestle Adds Peanut Allergy Treatment to Its Portfolio

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited have commented on Nestle after it announced its definitive agreement to purchase biopharma company Aimmune for $2.6 billion.

Oak Stone Limited Comments On Nestle As They Agree To Acquire Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle (SWX: NESN) on Monday expressed plans of buying Aimmune Therapeutics for £1.95 billion. The Brisbane-based biopharmaceutical company is largely known for its peanut allergy treatment.

Nestle wishes to acquire Aimmune Therapeutics for £1.95 billion

Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.

Nestle pays $2 billion to secure Aimmune's allergy treatment

Nestle S.A. (OTC: NSRGY) subsidiary Nestle Health Sciences (NHSc) is aquiring biopharma company Aimmune Therapeutics, Inc.

Aimmune Shares Surge 170% As Nestle Set To Acquire Company At $2.6B Enterprise Value

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio.

Nestle to buy Aimmune Therapeutics for $2.6 billion

This press release is also available in Français (pdf) and Deutsch (pdf)

Nestlé to acquire Aimmune Therapeutics

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc.

Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science

Nestlé: Focusing Its Efforts In The Right Places

LM Ericsson Telefon

Franco-Nevada C

Pembina Pipeline

The U.S. may be the top global market, but these international stocks are red-hot. Travel the world and boost your portfolio.

6 International Stocks to Buy for Impressive Returns Now

Food giant Nestle is launching a new plant-based tuna alternative in Switzerland this month ahead of a global rollout, hoping that consumers eating at home during the COVID-19 pandemic will stay eager to try new products.

Nestle launches vegan alternative to tuna

LVMH Moet Hennessy Louis Vuitton

Flutter Entertainment PLC

Tencent Holdings Limited

Some OTC stocks are big, familiar names with credible business models and powerful brands. Investors shouldn't pass on this exciting space.

7 OTC Stocks Perfect for Ordinary Investors

AstraZeneca

iShares Europe ETF

Active traders have been focused on North America, but these charts suggest that it's a good time to add exposure to European equities.

Charts Suggest It's Time to Invest in European Equities

Nestle SA (NSRGY) CEO Mark Schneider on Q2 2020 Results - Earnings Call Transcript

Nestle will keep making sure earnings and sales growth remained balanced, its chief executive told investors on a call after the food group posted better-than-expected results for the first half of 2020.

Nestle wants to keep earnings and sales growth in balance

Nestle struck a more optimistic note than peers on Thursday, forecasting 2-3% underlying sales growth this year as demand for high-end pet food and health products helped it eke out growth in the second quarter.

Nestle more upbeat than rivals as pet lovers prop up sales

Food group Nestle on Thursday cut its full-year underlying sales forecast after strong consumer stockpiling at the start of coronavirus related-lockdowns in Europe and North America was followed by weaker demand in the second quarter.

Nestle cuts 2020 growth forecast after second-quarter sales slow

Organic growth reached 2.8%, with real internal growth (RIG) of 2.6% and pricing of 0.2%. Growth was supported by sustained momentum in the Americas, Purina PetCare and Nestlé Health Science.

Nestlé reports half-year results for 2020

Through The Lens Of The DuPont Method: The Nestlé Story

Nestle: Strong Trends In Profitability To Drive Shares Forward

News for Nestle SA Stock (NSRGY)